Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohn's Disease

被引：23
|
作者：
Huff-Hardy, Kayci [1 ]
Bedair, Mai [2 ]
Vazquez, Rebecca [2 ]
Burstein, Ezra [1 ]
机构：
[1] UT Southwestern Med Ctr, Dept Internal Med, Dallas, TX 75390 USA
[2] UT Southwestern Med Ctr, Dept Dermatol, Dallas, TX USA
来源：
INFLAMMATORY BOWEL DISEASES | 2017年 / 23卷 / 10期
关键词：
MAINTENANCE THERAPY; INDUCTION;
D O I：
10.1097/MIB.0000000000001232
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：E49 / E49
页数：1
相关论文
共 50 条
  • [1] Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease
    Alric, Hadrien
    Amiot, Aurelien
    Kirchgesner, Julien
    Treton, Xavier
    Allez, Mathieu
    Bouhnik, Yoram
    Beaugerie, Laurent
    Carbonnel, Franck
    Meyer, Antoine
    INFLAMMATORY BOWEL DISEASES, 2022, 28 (02) : 218 - 225
  • [2] EFFICACY AND SAFETY OF USTEKINUMAB AND VEDOLIZUMAB FOR CROHN'S DISEASE OF THE POUCH
    Park, Sunhee
    Keyashian, Kian
    Ho, Andrew
    Limsui, David
    Frost, Spencer
    Vazquez-Reyes, Raul
    Ebriani, Joseph
    Yang, Eleanor
    Parekh, Nimisha K.
    Sauk, Jenny S.
    Limketkai, Berkeley N.
    GASTROENTEROLOGY, 2022, 162 (07) : S146 - S146
  • [3] Dual biologic therapy with Vedolizumab and Ustekinumab for refractory Crohn's disease in children
    Howard, Gadi
    Weiner, Dror
    Bar-Or, Itzhak
    Levine, Arie
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (04) : 372 - 374
  • [4] The Use of Combination Vedolizumab and Ustekinumab in Crohn's Disease: A Retrospective Cohort Study
    Glassner, Kerri
    Wang, Lin
    Ezeana, Chika
    Wong, Stephen
    Abraham, Bincy P.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S355 - S355
  • [5] DEEP REMISSION WITH DOUBLE BIOLOGIC THERAPY: A SUCCESSFUL CASE OF COMBINATION USTEKINUMAB AND VEDOLIZUMAB FOR SEVERE REFRACTORY CROHN'S DISEASE
    Elmoursi, Ahmed
    Perry, Courtney
    Barrett, Terrence
    INFLAMMATORY BOWEL DISEASES, 2020, 26 : S72 - S72
  • [6] DEEP REMISSION WITH DOUBLE BIOLOGIC THERAPY: A SUCCESSFUL CASE OF COMBINATION USTEKINUMAB AND VEDOLIZUMAB FOR SEVERE REFRACTORY CROHN'S DISEASE
    Elmoursi, Ahmed
    Perry, Courtney
    Barrett, Terrence
    GASTROENTEROLOGY, 2020, 158 (03) : S117 - S118
  • [7] Long term efficacy of ustekinumab in Crohn's disease patients after vedolizumab failure
    Melotti, L.
    Dussias, N. K.
    Belluzzi, A.
    Salice, M.
    Calabrese, C.
    Rizzello, F.
    Gionchetti, P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I408 - I408
  • [8] Long term efficacy of ustekinumab in Crohn's disease patients after vedolizumab failure
    Melotti, L.
    Dussias, N. K.
    Belluzzi, A.
    Salice, M.
    Calabrese, C.
    Rizzello, F.
    Gionchetti, P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I408 - I408
  • [9] The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn's Disease
    Macaluso, F. S.
    Grova, M.
    Saladino, M.
    Demarzo, M. G.
    Privitera, A. C.
    Giangreco, E.
    Garufi, S.
    Renna, S.
    Casa, A.
    Ventimiglia, M.
    Cappello, M.
    Fries, W.
    Orlando, A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I359 - I359
  • [10] The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab
    Kassouri, Liza
    Amiot, Aurelien
    Kirchgesner, Julien
    Treton, Xavier
    Allez, Mathieu
    Bouhnik, Yoram
    Beaugerie, Laurent
    Carbonnel, Franck
    Meyer, Antoine
    DIGESTIVE AND LIVER DISEASE, 2020, 52 (10) : 1148 - 1155
12345